Libutti Steven K, Crabtree Judy S, Lorang Dominique, Burns A Lee, Mazzanti Chiara, Hewitt Stephen M, O'Connor Sarah, Ward Jerrold M, Emmert-Buck Michael R, Remaley Alan, Miller Marshall, Turner Ewa, Alexander H Richard, Arnold Andrew, Marx Stephen J, Collins Francis S, Spiegel Allen M
Surgery Branch, Center for Cancer Research, National Cancer Institute/NIH, 10 Center Drive, Room 2B07, Bethesda, MD 20892, USA.
Cancer Res. 2003 Nov 15;63(22):8022-8.
The inactivation of the MEN1 tumor suppressor gene in patients leads to a constellation of changes in endocrine tissues, including parathyroid neoplasia, pituitary adenomas, pancreatic neuroendocrine tumors, and carcinoids. To study the pathophysiological consequences of the deletion of the MEN1 gene, we set out to create a mouse model of hyperparathyroidism resulting from the deletion of the Men1 gene in parathyroid tissue. We introduced a Men1 gene flanked by loxP sites into the mouse germ line and then used a parathyroid cell-specific promoter to drive the expression of Cre recombinase, resulting in the deletion of the Men1 gene. Here, we show that loss of Men1 gene function in the parathyroid glands of mice results in histological changes consistent with parathyroid neoplasia as well as systemic hypercalcemia. This model provides a means for dissecting the molecular basis of this familial cancer syndrome and may allow for the development of new strategies to treat related forms of hypercalcemia.